Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by American Century Companies Inc.

American Century Companies Inc. lifted its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 25.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 314,362 shares of the biopharmaceutical company's stock after buying an additional 63,423 shares during the period. American Century Companies Inc. owned about 0.30% of Intra-Cellular Therapies worth $26,256,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the business. Wasatch Advisors LP grew its holdings in Intra-Cellular Therapies by 3.5% during the third quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company's stock worth $281,601,000 after acquiring an additional 130,351 shares during the period. Bellevue Group AG grew its stake in shares of Intra-Cellular Therapies by 0.6% during the 3rd quarter. Bellevue Group AG now owns 2,485,627 shares of the biopharmaceutical company's stock worth $181,873,000 after purchasing an additional 14,342 shares during the period. State Street Corp grew its stake in shares of Intra-Cellular Therapies by 3.1% during the 3rd quarter. State Street Corp now owns 1,858,915 shares of the biopharmaceutical company's stock worth $136,017,000 after purchasing an additional 56,664 shares during the period. Franklin Resources Inc. increased its holdings in shares of Intra-Cellular Therapies by 9.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company's stock valued at $129,463,000 after purchasing an additional 155,655 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Intra-Cellular Therapies by 1.3% in the third quarter. Geode Capital Management LLC now owns 1,708,301 shares of the biopharmaceutical company's stock valued at $125,029,000 after purchasing an additional 22,128 shares during the period. 92.33% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analyst Weigh In

Several research analysts have weighed in on ITCI shares. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and upped their target price for the stock from $119.00 to $132.00 in a research report on Friday, January 31st. Royal Bank of Canada restated a "sector perform" rating and issued a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Needham & Company LLC reaffirmed a "hold" rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Piper Sandler reissued a "neutral" rating and issued a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Finally, Leerink Partnrs downgraded Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Eleven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $106.23.

Intra-Cellular Therapies Stock Performance

Shares of NASDAQ:ITCI remained flat at $131.87 during trading on Thursday. The stock has a market capitalization of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69. The business has a 50-day simple moving average of $129.53 and a 200-day simple moving average of $101.03. Intra-Cellular Therapies, Inc. has a one year low of $64.09 and a one year high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million during the quarter, compared to analysts' expectations of $205.08 million. On average, equities analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.